Diagnostic imaging company RadNet, via DeepHealth, its wholly-owned subsidiary, has acquired AI ultrasound imaging company See-Mode Technologies.
See-Mode’s AI-powered ultrasound detection, characterization and reporting application for thyroid and breast will be integrated into RadNet’s DeepHealth population health offerings.
According to RadNet, See-Mode’s original applications for detecting and characterizing thyroid nodules and breast lesions in ultrasound imaging “improve diagnostic accuracy and enhance clinical workflows by generating standardized reports.”
“Early deployment of See-Mode’s FDA-approved thyroid ultrasound AI across a portion of our imaging centers has demonstrated up to a 30% reduction in scan time as a result of increased workflow efficiency from See-Mode’s automated detection and reporting,” Dr. Howard Berger, president and CEO of RadNet, said in a statement.
“With demand exceeding available appointment slots for many of our over 900 ultrasound units, the increase in capacity created by See-Mode’s technology should improve our ability to drive better access and more revenue through RadNet’s existing centers.”
THE LARGER TREND
In 2024, GE HealthCare and DeepHealth collaborated on an AI imaging technology to further innovation, commercialization and adoption of AI in imaging.
As part of the collaboration, the companies said they would co-develop Smart Technology solutions that leverage the power of AI to address obstacles across the imaging value chain, such as imaging interpretation efficiency, reporting and facilitating collaboration across care teams, improving the clinical interpretation of images and strengthening operational efficiency and productivity.
In 2022, Volpara Health Technologies signed a use contract with RadNet for the deployment of Volpara Analytics and Volpara Risk Pathways software across RadNet’s 353 imaging centers in seven U.S. states. In 2024, See-Mode obtained 510(k) clearance from the FDA for an AI-powered offering to detect and diagnose thyroid issues in ultrasound scans.
A year before, See-Mode obtained regulatory approvals in Australia and New Zealand for its AI-powered breast and thyroid ultrasound offering.
